ES2196547T3 - Tratamiento de infartos por inhibicion de nf-kappab. - Google Patents

Tratamiento de infartos por inhibicion de nf-kappab.

Info

Publication number
ES2196547T3
ES2196547T3 ES98906511T ES98906511T ES2196547T3 ES 2196547 T3 ES2196547 T3 ES 2196547T3 ES 98906511 T ES98906511 T ES 98906511T ES 98906511 T ES98906511 T ES 98906511T ES 2196547 T3 ES2196547 T3 ES 2196547T3
Authority
ES
Spain
Prior art keywords
kappab
infartos
inhibition
treatment
ubiquitin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98906511T
Other languages
English (en)
Inventor
Stephen Brand
Alfred L Goldberg
Louis Plamondon
Francois Soucy
Peter J Elliot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2196547T3 publication Critical patent/ES2196547T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Insulating Materials (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicinal Preparation (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
  • Transplanting Machines (AREA)
  • Artificial Filaments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere al tratamiento de la isquemia por medio de la administración de inhibidores de proteasoma, inhibidores de la ruta de ubiquitina, agentes que interfieren con la activación de NF-{ka}B por medio de la ruta de ubiquitina proteasoma, o mezclas de los mismos.
ES98906511T 1997-02-15 1998-02-17 Tratamiento de infartos por inhibicion de nf-kappab. Expired - Lifetime ES2196547T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80193697A 1997-02-15 1997-02-15
US98833997A 1997-12-03 1997-12-03

Publications (1)

Publication Number Publication Date
ES2196547T3 true ES2196547T3 (es) 2003-12-16

Family

ID=27122399

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98906511T Expired - Lifetime ES2196547T3 (es) 1997-02-15 1998-02-17 Tratamiento de infartos por inhibicion de nf-kappab.

Country Status (15)

Country Link
US (3) US6271199B2 (es)
EP (1) EP0979096B1 (es)
JP (1) JP2001511814A (es)
CN (1) CN1159061C (es)
AT (1) ATE240113T1 (es)
AU (1) AU741802B2 (es)
CA (1) CA2281224A1 (es)
DE (1) DE69814618T2 (es)
ES (1) ES2196547T3 (es)
HK (1) HK1025266A1 (es)
IL (1) IL131410A0 (es)
NO (1) NO321203B1 (es)
NZ (1) NZ337364A (es)
PT (1) PT979096E (es)
WO (1) WO1998035691A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1008352A4 (en) * 1997-07-04 2005-03-16 Fujisawa Pharmaceutical Co Cerebrospinal PROTECTOR
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20090042807A1 (en) * 1998-05-20 2009-02-12 Nisar Ahmed Khan Oligopeptide treatment of ischemia reperfusion injury
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
WO2001019376A2 (en) * 1999-09-13 2001-03-22 Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US6713459B1 (en) * 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
AU4322802A (en) 2000-11-16 2002-06-24 Univ California Marine actinomycete taxon for drug and fermentation product dicovery
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
DK1392355T3 (da) 2001-05-21 2007-04-30 Alcon Inc Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
EP1448205B1 (en) * 2001-10-05 2011-03-23 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
US20030139458A1 (en) * 2001-12-10 2003-07-24 Yansheng Du Treatment of neurodegenerative and cardiovascular disorders
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
NZ544588A (en) * 2003-06-20 2010-06-25 Nereus Pharmaceuticals Inc Use of salinosporamide A and analogs thereof for the treatment of cancer, inflammation and infectious diseases
ZA200600473B (en) * 2003-06-20 2007-04-25 Univ California Salinosporamides and methods for use thereof
WO2005023187A2 (en) 2003-08-28 2005-03-17 Kem David C Inhibitor of cardiac tachyarrhythmias
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
SE0400399D0 (sv) * 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
EP1812443A2 (en) * 2004-04-30 2007-08-01 Nereus Pharmaceuticals, Inc. [3.2.0] heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7425580B2 (en) * 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
WO2006002453A2 (en) * 2004-07-07 2006-01-12 Biodevelops Pharma Entwicklung Gmbh Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface
US20060008454A1 (en) * 2004-07-07 2006-01-12 Dr. Helmut Brunar Use of a compound for enhancing the expression of membrane proteins on the cell surface
KR20070058463A (ko) * 2004-08-30 2007-06-08 도레이 가부시끼가이샤 분획 장치
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
US20070225350A1 (en) 2004-12-03 2007-09-27 Anderson Kenneth C Compositions and methods for treating neoplastic diseases
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
EP1912664A2 (en) * 2005-07-06 2008-04-23 Biodevelops Pharma Entwicklung GmbH Use of a compound for enhancing the expression of membrane proteins on the cell surface
WO2007011757A1 (en) * 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
US7691896B2 (en) * 2005-08-10 2010-04-06 President And Fellows Of Harvard College Analogs of salinosporamide A
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
ES2293834B1 (es) * 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
AU2008215193B2 (en) * 2007-02-12 2014-01-16 Biotempt B.V. Treatment of trauma hemorrhage with short oligopeptides
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
MX2010012341A (es) * 2008-05-12 2010-12-06 Nereus Pharmaceuticals Inc Derivados de salinosporamida como inhibidores de proteasoma.
KR101690571B1 (ko) 2008-06-17 2016-12-28 밀레니엄 파머슈티컬스 인코퍼레이티드 보로네이트 에스테르 화합물 및 이의 제약학적 조성물
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
WO2011090159A1 (ja) 2010-01-22 2011-07-28 独立行政法人科学技術振興機構 蛋白質の分解活性を測定するためのプローブ試薬
CN102892291A (zh) 2010-03-31 2013-01-23 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
CN108498532B (zh) 2012-05-09 2021-07-23 坎泰克斯制药股份有限公司 骨髓抑制的治疗
ZA201402789B (en) 2013-04-16 2015-11-25 Cipla Ltd Process for the preparation of bortezomib mannitol ester
CN111116622A (zh) 2014-02-03 2020-05-08 俄亥俄州创新基金会 硼酸酯和其药物制剂
KR102481856B1 (ko) 2014-05-20 2022-12-26 밀레니엄 파머슈티컬스 인코퍼레이티드 일차 암 치료법 후 사용하기 위한 붕소-함유 프로테아좀 저해제
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
EP3270891A1 (en) 2015-03-17 2018-01-24 Leon-Nanodrugs GmbH Nanoparticles comprising a stabilized boronic acid compound
US11897969B2 (en) 2017-10-26 2024-02-13 The Regents Of The University Of California Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97428A0 (en) 1990-03-05 1992-06-21 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
ATE357922T1 (de) * 1995-05-12 2007-04-15 Anges Mg Inc Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen
US5942494A (en) 1995-10-06 1999-08-24 The Trustees Of Columbia University In The City Of New York Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70)
KR20000064670A (ko) 1996-03-19 2000-11-06 부르너 데이빗 ＩκＢα를 부위특이적 인산화시킬 수 있는 키나아제
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof

Also Published As

Publication number Publication date
EP0979096B1 (en) 2003-05-14
HK1025266A1 (en) 2000-11-10
NO993935D0 (no) 1999-08-16
DE69814618D1 (de) 2003-06-18
AU741802B2 (en) 2001-12-13
JP2001511814A (ja) 2001-08-14
DE69814618T2 (de) 2004-03-25
CN1250376A (zh) 2000-04-12
CN1159061C (zh) 2004-07-28
US20010053760A1 (en) 2001-12-20
US20030069189A1 (en) 2003-04-10
US6271199B2 (en) 2001-08-07
US20010002391A1 (en) 2001-05-31
AU6171998A (en) 1998-09-08
NO321203B1 (no) 2006-04-03
WO1998035691A1 (en) 1998-08-20
EP0979096A1 (en) 2000-02-16
NZ337364A (en) 2001-06-29
NO993935L (no) 1999-10-04
PT979096E (pt) 2003-09-30
CA2281224A1 (en) 1998-08-20
ATE240113T1 (de) 2003-05-15
IL131410A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
ES2196547T3 (es) Tratamiento de infartos por inhibicion de nf-kappab.
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
BG104247A (en) Resorcinol derivatives
TR199701074T1 (xx) Sinerjistik bile�imler.
BR9812357A (pt) Tratamento de distúbio oposicional desafiador
AP9200410A0 (en) Retroviral protease inhibitors.
TR199902751T2 (xx) Proteaz inhibit�rleri.
DK0934065T3 (da) Hidtil ukendte cruptophycinderivater som antieoplastiske midler
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
BR9808299A (pt) O uso de levobupivacaìna ou ropivacaìna para o tratamento da enxaqueca
ATE333277T1 (de) Behandlung von dyskinesie
ATE322898T1 (de) Inhibitoren von mycobakterien
DK1042288T3 (da) Tripeptidyl-peptidase inhibitorer
DE59813914D1 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
ATE337004T1 (de) Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
BR0314364A (pt) Uso de inibidores de pde iv para tratar angiogênese
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
AU2003282035A1 (en) Modulation of s6 kinase activity for the treatment of obestiy
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.
AR021749A1 (es) Uso de derivados de tiazolidinediona para el tratamiento o prevencion de cataratas.